CAR-T Cell Therapy Market Forecasts to 2030 - Global Analysis By Drug Type (Brexucabtagene Autoleucel, Axicabtagene Ciloleucel, Tisagenlecleucel and Other Drug Types), Target Antigen, Application, End User and By Geography

Description

List of Tables

According to Stratistics MRC, the Global CAR-T Cell Therapy Market is accounted for $3.3 billion in 2023 and is expected to reach $21.8 billion by 2030 growing at a CAGR of 30.5% during the forecast period. CAR-T cell therapy, short for chimeric antigen receptor T-cell therapy, is a groundbreaking form of immunotherapy used in the treatment of certain types of cancer. It involves genetically modifying a patient's own T cells (a type of immune cell) to express chimeric antigen receptors (CARs) on their surface. The process typically starts by collecting T cells from the patient's blood through a process called leukapheresis. These T cells are then genetically engineered in a laboratory to express specific receptors called CARs on their surface. These receptors are designed to recognize and bind to specific proteins, typically found on the surface of cancer cells.

According to the cancer data published by World Cancer Research Fund International, there were 474,519 new cases of leukemia, 176,404 new cases of multiple myeloma and 627,439 new cases of lymphoma worldwide in 2020.

Market Dynamics:

Driver:

Increasing prevalence of cancer

Despite the promising advancements in CAR-T technology, the rise in cancer incidence poses significant challenges. Factors such as aging populations, environmental factors, and lifestyle changes contribute to this trend. As the demand for effective cancer treatments grows, addressing this rising prevalence becomes imperative for healthcare providers and researchers in the field of CAR-T therapy. Thus, the market is experiencing a concerning trend with an increasing prevalence of cancer cases.

Restraint:

Limited number of approved therapies

In the rapidly evolving field of CAR-T cell therapy, only a limited number of treatments have gained approval. These therapies have shown remarkable efficacy in treating certain types of blood cancers, including leukemia and lymphoma. However, the market remains relatively constrained due to high costs, complex manufacturing processes, and the need for further research to expand indications and improve safety profiles.

Opportunity:

Advancements in technology

Advancements in CAR-T cell therapy have revolutionized cancer treatment, offering personalized immunotherapy solutions. Enhanced manufacturing techniques, such as lent viral vector design and automated cell processing systems, streamline production, improving scalability and reducing costs. Targeted modifications to CAR constructs enhance tumour specificity and reduce off-target effects, boosting therapeutic efficacy.

Threat:

High manufacturing costs

The market faces significant manufacturing costs, primarily due to the complex and labor-intensive process involved. Manufacturing CAR-T cells requires sophisticated cell engineering techniques, extensive quality control measures, and specialized infrastructure. Additionally, personalized nature of the therapy adds to the expenses, as each treatment is tailored to individual patients. These high costs pose challenges for widespread adoption and accessibility of CAR-T cell therapy, limiting its availability to a broader patient population.

Covid-19 Impact:

The COVID-19 pandemic has significantly impacted the CAR-T cell therapy market, causing disruptions in clinical trials, manufacturing, and patient access. Supply chain disruptions and reduced hospital capacity have delayed treatments and hindered market growth. Additionally, diverted resources and prioritization of COVID-19 care have diverted attention from CAR-T therapy development and deployment. Despite challenges, increased focus on immunotherapy and innovative treatments may drive market recovery and growth in the long term.

The tisagenlecleucel segment is expected to be the largest during the forecast period

The tisagenlecleucel segment is expected to be the largest during the forecast period. Engineered to target specific cancer cells, it has shown remarkable efficacy in patients with certain types of leukemia and lymphoma. Its approval marked a significant milestone in immunotherapy, offering new hope for patients who have exhausted conventional treatments. With its success, Tisagenlecleucel has quickly become a pivotal player in the CAR-T cell therapy market, driving advancements and further research in the field.

The lymphoma segment is expected to have the highest CAGR during the forecast period

The lymphoma segment is expected to have the highest CAGR during the forecast period driven by advancements in immunotherapy. CAR-T cell therapy involves modifying a patient's own immune cells to better recognize and attack cancer cells. This personalized approach has shown promising results in various lymphoma subtypes, particularly in patients who have not responded to conventional treatments. With ongoing research and clinical trials, the market for therapy in lymphoma is poised for further growth.

Region with largest share:

North America is projected to hold the largest market share during the forecast period. With a focus on personalized medicine, CAR-T therapies are gaining traction for treating various types of cancers, including leukemia and lymphoma. The region's robust healthcare infrastructure, coupled with supportive regulatory frameworks, fosters market expansion. Moreover, collaborations between pharmaceutical companies and academic institutions contribute to accelerating innovation in this promising field, promising a bright outlook for the market.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period. The rising prevalence of cancer in countries, coupled with growing awareness and improved diagnosis, was creating a larger pool of patients who could potentially benefit from CAR-T cell therapy. There was a significant increase in the number of clinical trials for CAR-T cell therapies being conducted in countries. These trials were evaluating the safety and efficacy of various CAR-T treatments across different types of cancer, contributing to the advancement of the field in the region.

Key players in the market

Some of the key players in CAR-T Cell Therapy market include Gilead Sciences Inc., Bristol-Myers Squibb, Novartis AG, Cartesian Therapeutics Inc., Merck & Co. Inc., Intellia Therapeutics, Juno Therapeutics Inc., Bluebird Bio Inc., Sorrento Therapeutics Inc., Autolus Therapeutics, Caribou Biosciences Inc., Miltenyi Biotech, Celgene Corporation, Aurora Biopharma Inc. and Pfizer, Inc.

Key Developments:

In December 2023, Bristol-Myers Squibb announced that it received manufacturing and marketing approval of the supplemental New Drug Application for an additional indication for Abecma (idecabtagene vicleucel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy.

In May 2023, Autolus Therapeutics plc announced that the abstract for the pivotal Phase 2 FELIX study of obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL) has been selected for an oral presentation at the European Hematology Association (EHA) 2023 Congress.

Drug Types Covered:

Brexucabtagene Autoleucel
Axicabtagene Ciloleucel
Tisagenlecleucel
Other Drug Types

Target Antigens Covered:

CD19
B-Cell Maturation Antigen (BCMA)
GD2
CD20
Other Target Antigens

Applications Covered:

Acute Lymphocytic Leukemia
Lymphoma
Chronic Lymphocytic Leukemia
Follicular Lymphoma
Hepatocellular Carcinoma
Colorectal Cancer
Other Applications

End Users Covered:

Cancer Treatment Centers
Hospitals
Other End Users

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Product Code: SMRC25621

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Application Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global CAR T-Cell Therapy Market, By Drug Type

5.1 Introduction
5.2 Brexucabtagene Autoleucel
5.3 Axicabtagene Ciloleucel
5.4 Tisagenlecleucel
5.5 Other Drug Types

6 Global CAR T-Cell Therapy Market, By Target Antigen

6.1 Introduction
6.2 CD19
6.3 B-Cell Maturation Antigen (BCMA)
6.4 GD2
6.5 CD20
6.6 Other Target Antigens

7 Global CAR T-Cell Therapy Market, By Application

7.1 Introduction
7.2 Acute Lymphocytic Leukemia
7.3 Lymphoma
7.4 Chronic Lymphocytic Leukemia
7.5 Follicular Lymphoma
7.6 Hepatocellular Carcinoma
7.7 Colorectal Cancer
7.8 Other Applications

8 Global CAR T-Cell Therapy Market, By End User

8.1 Introduction
8.2 Cancer Treatment Centers
8.3 Hospitals
8.4 Other End Users

9 Global CAR T-Cell Therapy Market, By Geography

9.1 Introduction
9.2 North America
- 9.2.1 US
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 Italy
- 9.3.4 France
- 9.3.5 Spain
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 New Zealand
- 9.4.6 South Korea
- 9.4.7 Rest of Asia Pacific
9.5 South America
- 9.5.1 Argentina
- 9.5.2 Brazil
- 9.5.3 Chile
- 9.5.4 Rest of South America
9.6 Middle East & Africa
- 9.6.1 Saudi Arabia
- 9.6.2 UAE
- 9.6.3 Qatar
- 9.6.4 South Africa
- 9.6.5 Rest of Middle East & Africa

10 Key Developments

10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies

11 Company Profiling

11.1 Gilead Sciences Inc.
11.2 Bristol-Myers Squibb
11.3 Novartis AG
11.4 Cartesian Therapeutics Inc.
11.5 Merck & Co. Inc.
11.6 Intellia Therapeutics
11.7 Juno Therapeutics Inc.
11.8 Bluebird Bio Inc.
11.9 Sorrento Therapeutics Inc.
11.10 Autolus Therapeutics
11.11 Caribou Biosciences Inc.
11.12 Miltenyi Biotech
11.13 Celgene Corporation
11.14 Aurora Biopharma Inc.
11.15 Pfizer, Inc.

Product Code: SMRC25621

List of Tables

Table 1 Global CAR T-Cell Therapy Market Outlook, By Region (2021-2030) ($MN)
Table 2 Global CAR T-Cell Therapy Market Outlook, By Drug Type (2021-2030) ($MN)
Table 3 Global CAR T-Cell Therapy Market Outlook, By Brexucabtagene Autoleucel (2021-2030) ($MN)
Table 4 Global CAR T-Cell Therapy Market Outlook, By Axicabtagene Ciloleucel (2021-2030) ($MN)
Table 5 Global CAR T-Cell Therapy Market Outlook, By Tisagenlecleucel (2021-2030) ($MN)
Table 6 Global CAR T-Cell Therapy Market Outlook, By Other Drug Types (2021-2030) ($MN)
Table 7 Global CAR T-Cell Therapy Market Outlook, By Target Antigen (2021-2030) ($MN)
Table 8 Global CAR T-Cell Therapy Market Outlook, By CD19 (2021-2030) ($MN)
Table 9 Global CAR T-Cell Therapy Market Outlook, By B-Cell Maturation Antigen (BCMA) (2021-2030) ($MN)
Table 10 Global CAR T-Cell Therapy Market Outlook, By GD2 (2021-2030) ($MN)
Table 11 Global CAR T-Cell Therapy Market Outlook, By CD20 (2021-2030) ($MN)
Table 12 Global CAR T-Cell Therapy Market Outlook, By Other Target Antigens (2021-2030) ($MN)
Table 13 Global CAR T-Cell Therapy Market Outlook, By Application (2021-2030) ($MN)
Table 14 Global CAR T-Cell Therapy Market Outlook, By Acute Lymphocytic Leukemia (2021-2030) ($MN)
Table 15 Global CAR T-Cell Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
Table 16 Global CAR T-Cell Therapy Market Outlook, By Chronic Lymphocytic Leukemia (2021-2030) ($MN)
Table 17 Global CAR T-Cell Therapy Market Outlook, By Follicular Lymphoma (2021-2030) ($MN)
Table 18 Global CAR T-Cell Therapy Market Outlook, By Hepatocellular Carcinoma (2021-2030) ($MN)
Table 19 Global CAR T-Cell Therapy Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
Table 20 Global CAR T-Cell Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
Table 21 Global CAR T-Cell Therapy Market Outlook, By End User (2021-2030) ($MN)
Table 22 Global CAR T-Cell Therapy Market Outlook, By Cancer Treatment Centers (2021-2030) ($MN)
Table 23 Global CAR T-Cell Therapy Market Outlook, By Hospitals (2021-2030) ($MN)
Table 24 Global CAR T-Cell Therapy Market Outlook, By Other End Users (2021-2030) ($MN)
Table 25 North America CAR T-Cell Therapy Market Outlook, By Country (2021-2030) ($MN)
Table 26 North America CAR T-Cell Therapy Market Outlook, By Drug Type (2021-2030) ($MN)
Table 27 North America CAR T-Cell Therapy Market Outlook, By Brexucabtagene Autoleucel (2021-2030) ($MN)
Table 28 North America CAR T-Cell Therapy Market Outlook, By Axicabtagene Ciloleucel (2021-2030) ($MN)
Table 29 North America CAR T-Cell Therapy Market Outlook, By Tisagenlecleucel (2021-2030) ($MN)
Table 30 North America CAR T-Cell Therapy Market Outlook, By Other Drug Types (2021-2030) ($MN)
Table 31 North America CAR T-Cell Therapy Market Outlook, By Target Antigen (2021-2030) ($MN)
Table 32 North America CAR T-Cell Therapy Market Outlook, By CD19 (2021-2030) ($MN)
Table 33 North America CAR T-Cell Therapy Market Outlook, By B-Cell Maturation Antigen (BCMA) (2021-2030) ($MN)
Table 34 North America CAR T-Cell Therapy Market Outlook, By GD2 (2021-2030) ($MN)
Table 35 North America CAR T-Cell Therapy Market Outlook, By CD20 (2021-2030) ($MN)
Table 36 North America CAR T-Cell Therapy Market Outlook, By Other Target Antigens (2021-2030) ($MN)
Table 37 North America CAR T-Cell Therapy Market Outlook, By Application (2021-2030) ($MN)
Table 38 North America CAR T-Cell Therapy Market Outlook, By Acute Lymphocytic Leukemia (2021-2030) ($MN)
Table 39 North America CAR T-Cell Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
Table 40 North America CAR T-Cell Therapy Market Outlook, By Chronic Lymphocytic Leukemia (2021-2030) ($MN)
Table 41 North America CAR T-Cell Therapy Market Outlook, By Follicular Lymphoma (2021-2030) ($MN)
Table 42 North America CAR T-Cell Therapy Market Outlook, By Hepatocellular Carcinoma (2021-2030) ($MN)
Table 43 North America CAR T-Cell Therapy Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
Table 44 North America CAR T-Cell Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
Table 45 North America CAR T-Cell Therapy Market Outlook, By End User (2021-2030) ($MN)
Table 46 North America CAR T-Cell Therapy Market Outlook, By Cancer Treatment Centers (2021-2030) ($MN)
Table 47 North America CAR T-Cell Therapy Market Outlook, By Hospitals (2021-2030) ($MN)
Table 48 North America CAR T-Cell Therapy Market Outlook, By Other End Users (2021-2030) ($MN)
Table 49 Europe CAR T-Cell Therapy Market Outlook, By Country (2021-2030) ($MN)
Table 50 Europe CAR T-Cell Therapy Market Outlook, By Drug Type (2021-2030) ($MN)
Table 51 Europe CAR T-Cell Therapy Market Outlook, By Brexucabtagene Autoleucel (2021-2030) ($MN)
Table 52 Europe CAR T-Cell Therapy Market Outlook, By Axicabtagene Ciloleucel (2021-2030) ($MN)
Table 53 Europe CAR T-Cell Therapy Market Outlook, By Tisagenlecleucel (2021-2030) ($MN)
Table 54 Europe CAR T-Cell Therapy Market Outlook, By Other Drug Types (2021-2030) ($MN)
Table 55 Europe CAR T-Cell Therapy Market Outlook, By Target Antigen (2021-2030) ($MN)
Table 56 Europe CAR T-Cell Therapy Market Outlook, By CD19 (2021-2030) ($MN)
Table 57 Europe CAR T-Cell Therapy Market Outlook, By B-Cell Maturation Antigen (BCMA) (2021-2030) ($MN)
Table 58 Europe CAR T-Cell Therapy Market Outlook, By GD2 (2021-2030) ($MN)
Table 59 Europe CAR T-Cell Therapy Market Outlook, By CD20 (2021-2030) ($MN)
Table 60 Europe CAR T-Cell Therapy Market Outlook, By Other Target Antigens (2021-2030) ($MN)
Table 61 Europe CAR T-Cell Therapy Market Outlook, By Application (2021-2030) ($MN)
Table 62 Europe CAR T-Cell Therapy Market Outlook, By Acute Lymphocytic Leukemia (2021-2030) ($MN)
Table 63 Europe CAR T-Cell Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
Table 64 Europe CAR T-Cell Therapy Market Outlook, By Chronic Lymphocytic Leukemia (2021-2030) ($MN)
Table 65 Europe CAR T-Cell Therapy Market Outlook, By Follicular Lymphoma (2021-2030) ($MN)
Table 66 Europe CAR T-Cell Therapy Market Outlook, By Hepatocellular Carcinoma (2021-2030) ($MN)
Table 67 Europe CAR T-Cell Therapy Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
Table 68 Europe CAR T-Cell Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
Table 69 Europe CAR T-Cell Therapy Market Outlook, By End User (2021-2030) ($MN)
Table 70 Europe CAR T-Cell Therapy Market Outlook, By Cancer Treatment Centers (2021-2030) ($MN)
Table 71 Europe CAR T-Cell Therapy Market Outlook, By Hospitals (2021-2030) ($MN)
Table 72 Europe CAR T-Cell Therapy Market Outlook, By Other End Users (2021-2030) ($MN)
Table 73 Asia Pacific CAR T-Cell Therapy Market Outlook, By Country (2021-2030) ($MN)
Table 74 Asia Pacific CAR T-Cell Therapy Market Outlook, By Drug Type (2021-2030) ($MN)
Table 75 Asia Pacific CAR T-Cell Therapy Market Outlook, By Brexucabtagene Autoleucel (2021-2030) ($MN)
Table 76 Asia Pacific CAR T-Cell Therapy Market Outlook, By Axicabtagene Ciloleucel (2021-2030) ($MN)
Table 77 Asia Pacific CAR T-Cell Therapy Market Outlook, By Tisagenlecleucel (2021-2030) ($MN)
Table 78 Asia Pacific CAR T-Cell Therapy Market Outlook, By Other Drug Types (2021-2030) ($MN)
Table 79 Asia Pacific CAR T-Cell Therapy Market Outlook, By Target Antigen (2021-2030) ($MN)
Table 80 Asia Pacific CAR T-Cell Therapy Market Outlook, By CD19 (2021-2030) ($MN)
Table 81 Asia Pacific CAR T-Cell Therapy Market Outlook, By B-Cell Maturation Antigen (BCMA) (2021-2030) ($MN)
Table 82 Asia Pacific CAR T-Cell Therapy Market Outlook, By GD2 (2021-2030) ($MN)
Table 83 Asia Pacific CAR T-Cell Therapy Market Outlook, By CD20 (2021-2030) ($MN)
Table 84 Asia Pacific CAR T-Cell Therapy Market Outlook, By Other Target Antigens (2021-2030) ($MN)
Table 85 Asia Pacific CAR T-Cell Therapy Market Outlook, By Application (2021-2030) ($MN)
Table 86 Asia Pacific CAR T-Cell Therapy Market Outlook, By Acute Lymphocytic Leukemia (2021-2030) ($MN)
Table 87 Asia Pacific CAR T-Cell Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
Table 88 Asia Pacific CAR T-Cell Therapy Market Outlook, By Chronic Lymphocytic Leukemia (2021-2030) ($MN)
Table 89 Asia Pacific CAR T-Cell Therapy Market Outlook, By Follicular Lymphoma (2021-2030) ($MN)
Table 90 Asia Pacific CAR T-Cell Therapy Market Outlook, By Hepatocellular Carcinoma (2021-2030) ($MN)
Table 91 Asia Pacific CAR T-Cell Therapy Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
Table 92 Asia Pacific CAR T-Cell Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
Table 93 Asia Pacific CAR T-Cell Therapy Market Outlook, By End User (2021-2030) ($MN)
Table 94 Asia Pacific CAR T-Cell Therapy Market Outlook, By Cancer Treatment Centers (2021-2030) ($MN)
Table 95 Asia Pacific CAR T-Cell Therapy Market Outlook, By Hospitals (2021-2030) ($MN)
Table 96 Asia Pacific CAR T-Cell Therapy Market Outlook, By Other End Users (2021-2030) ($MN)
Table 97 South America CAR T-Cell Therapy Market Outlook, By Country (2021-2030) ($MN)
Table 98 South America CAR T-Cell Therapy Market Outlook, By Drug Type (2021-2030) ($MN)
Table 99 South America CAR T-Cell Therapy Market Outlook, By Brexucabtagene Autoleucel (2021-2030) ($MN)
Table 100 South America CAR T-Cell Therapy Market Outlook, By Axicabtagene Ciloleucel (2021-2030) ($MN)
Table 101 South America CAR T-Cell Therapy Market Outlook, By Tisagenlecleucel (2021-2030) ($MN)
Table 102 South America CAR T-Cell Therapy Market Outlook, By Other Drug Types (2021-2030) ($MN)
Table 103 South America CAR T-Cell Therapy Market Outlook, By Target Antigen (2021-2030) ($MN)
Table 104 South America CAR T-Cell Therapy Market Outlook, By CD19 (2021-2030) ($MN)
Table 105 South America CAR T-Cell Therapy Market Outlook, By B-Cell Maturation Antigen (BCMA) (2021-2030) ($MN)
Table 106 South America CAR T-Cell Therapy Market Outlook, By GD2 (2021-2030) ($MN)
Table 107 South America CAR T-Cell Therapy Market Outlook, By CD20 (2021-2030) ($MN)
Table 108 South America CAR T-Cell Therapy Market Outlook, By Other Target Antigens (2021-2030) ($MN)
Table 109 South America CAR T-Cell Therapy Market Outlook, By Application (2021-2030) ($MN)
Table 110 South America CAR T-Cell Therapy Market Outlook, By Acute Lymphocytic Leukemia (2021-2030) ($MN)
Table 111 South America CAR T-Cell Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
Table 112 South America CAR T-Cell Therapy Market Outlook, By Chronic Lymphocytic Leukemia (2021-2030) ($MN)
Table 113 South America CAR T-Cell Therapy Market Outlook, By Follicular Lymphoma (2021-2030) ($MN)
Table 114 South America CAR T-Cell Therapy Market Outlook, By Hepatocellular Carcinoma (2021-2030) ($MN)
Table 115 South America CAR T-Cell Therapy Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
Table 116 South America CAR T-Cell Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
Table 117 South America CAR T-Cell Therapy Market Outlook, By End User (2021-2030) ($MN)
Table 118 South America CAR T-Cell Therapy Market Outlook, By Cancer Treatment Centers (2021-2030) ($MN)
Table 119 South America CAR T-Cell Therapy Market Outlook, By Hospitals (2021-2030) ($MN)
Table 120 South America CAR T-Cell Therapy Market Outlook, By Other End Users (2021-2030) ($MN)
Table 121 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Country (2021-2030) ($MN)
Table 122 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Drug Type (2021-2030) ($MN)
Table 123 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Brexucabtagene Autoleucel (2021-2030) ($MN)
Table 124 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Axicabtagene Ciloleucel (2021-2030) ($MN)
Table 125 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Tisagenlecleucel (2021-2030) ($MN)
Table 126 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Other Drug Types (2021-2030) ($MN)
Table 127 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Target Antigen (2021-2030) ($MN)
Table 128 Middle East & Africa CAR T-Cell Therapy Market Outlook, By CD19 (2021-2030) ($MN)
Table 129 Middle East & Africa CAR T-Cell Therapy Market Outlook, By B-Cell Maturation Antigen (BCMA) (2021-2030) ($MN)
Table 130 Middle East & Africa CAR T-Cell Therapy Market Outlook, By GD2 (2021-2030) ($MN)
Table 131 Middle East & Africa CAR T-Cell Therapy Market Outlook, By CD20 (2021-2030) ($MN)
Table 132 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Other Target Antigens (2021-2030) ($MN)
Table 133 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Application (2021-2030) ($MN)
Table 134 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Acute Lymphocytic Leukemia (2021-2030) ($MN)
Table 135 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
Table 136 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Chronic Lymphocytic Leukemia (2021-2030) ($MN)
Table 137 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Follicular Lymphoma (2021-2030) ($MN)
Table 138 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Hepatocellular Carcinoma (2021-2030) ($MN)
Table 139 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
Table 140 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
Table 141 Middle East & Africa CAR T-Cell Therapy Market Outlook, By End User (2021-2030) ($MN)
Table 142 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Cancer Treatment Centers (2021-2030) ($MN)
Table 143 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Hospitals (2021-2030) ($MN)
Table 144 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Other End Users (2021-2030) ($MN)

CAR-T Cell Therapy Market Forecasts to 2030 - Global Analysis By Drug Type (Brexucabtagene Autoleucel, Axicabtagene Ciloleucel, Tisagenlecleucel and Other Drug Types), Target Antigen, Application, End User and By Geography

Description

Table of Contents

List of Tables

Market Dynamics:

Driver:

Restraint:

Opportunity:

Threat:

Covid-19 Impact:

Region with largest share:

Region with highest CAGR:

Key Developments:

Drug Types Covered:

Target Antigens Covered:

Applications Covered:

End Users Covered:

Regions Covered:

What our report offers:

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Table of Contents

1 Executive Summary

2 Preface

3 Market Trend Analysis

4 Porters Five Force Analysis

5 Global CAR T-Cell Therapy Market, By Drug Type

6 Global CAR T-Cell Therapy Market, By Target Antigen

7 Global CAR T-Cell Therapy Market, By Application

8 Global CAR T-Cell Therapy Market, By End User

9 Global CAR T-Cell Therapy Market, By Geography

10 Key Developments

11 Company Profiling

List of Tables